Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

Research

Estimated Incidence of Antimicrobial Drug–Resistant Nontyphoidal Salmonella Infections, United States, 2004–2012

Felicita MedallaComments to Author , Weidong Gu, Barbara E. Mahon, Michael Judd, Jason P. Folster, Patricia M. Griffin, and Robert M. Hoekstra
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 2

Estimated incidence of infection with all NTS and major serotypes with clinically important resistance (no. infections per 100,000 person-years), by state and resistance category, United States, 2004–2012. Estimates were derived by using Bayesian hierarchical models. All NTS includes the 4 major and other serotypes. Isolates in each category may have resistance to other agents. Data on Cipro among Newport (8 isolates), Cipro among Heidelberg (7), and Cef/Amp among Enteritidis (2) were too sparse

Figure 2. Estimated incidence of infection with all NTS and major serotypes with clinically important resistance (no. infections per 100,000 person-years), by state and resistance category, United States, 2004–2012. Estimates were derived by using Bayesian hierarchical models. All NTS includes the 4 major and other serotypes. Isolates in each category may have resistance to other agents. Data on Cipro among Newport (8 isolates), Cipro among Heidelberg (7), and Cef/Amp among Enteritidis (2) were too sparse to use in the Bayesian hierarchical models. Overall resistance was defined as Cipro, Cef/Amp, or Amp-only. Amp-only, resistant to ampicillin (MIC >32 μg/mL) but susceptible to ceftriaxone and ciprofloxacin; Cef/Amp, resistant to ceftriaxone (MIC >4 μg/mL) and ampicillin; Cipro, nonsusceptible to ciprofloxacin (MIC >0.12 μg /mL) but susceptible to ceftriaxone; NTS, nontyphoidal Salmonella.

Main Article

TOP